XERS vs LNTH vs SUPN vs PAHC vs CORT

For growth investors, Xeris Biopharma Holdings, Inc.

(XERS) is the stronger pick with 43. 7% revenue growth year-over-year, versus 0. 5% for Lantheus Holdings, Inc. (LNTH). Lantheus Holdings, Inc. (LNTH) offers the better valuation at 26. 7x trailing P/E (17. 5x forward), making it the more compelling value choice. Analysts rate Xeris Biopharma Holdings, Inc. (XERS) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Lantheus Holdings, Inc.

(LNTH) is the cheapest at 26. 7x versus Xeris Biopharma Holdings, Inc. at 2071. 9x. On forward P/E, Phibro Animal Health Corporation is actually cheaper at 14. 2x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Lantheus Holdings, Inc.

(LNTH) delivered a total return of +314. 2%, compared to +66. 0% for Phibro Animal Health Corporation (PAHC). Over 10 years, the gap is even starker: LNTH returned +41. 9% versus XERS's -67. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Lantheus Holdings, Inc.

(LNTH) is the lower-risk stock at 0. 47β versus Corcept Therapeutics Incorporated's 1. 78β — meaning CORT is approximately 279% more volatile than LNTH relative to the S&P 500. On balance sheet safety, Lantheus Holdings, Inc. (LNTH) carries a lower debt/equity ratio of 0% versus 3% for Xeris Biopharma Holdings, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Xeris Biopharma Holdings, Inc.

(XERS) is pulling ahead at 43. 7% versus 0. 5% for Lantheus Holdings, Inc. (LNTH). On earnings-per-share growth, the picture is similar: Phibro Animal Health Corporation grew EPS 1883% year-over-year, compared to -151. 5% for Supernus Pharmaceuticals, Inc.. Over a 3-year CAGR, XERS leads at 38. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Lantheus Holdings, Inc.

(LNTH) is the more profitable company, earning 15. 2% net margin versus -5. 4% for Supernus Pharmaceuticals, Inc. — meaning it keeps 15. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LNTH leads at 20. 2% versus -5. 1% for SUPN. At the gross margin level — before operating expenses — CORT leads at 98. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Phibro Animal Health Corporation (PAHC) trades at 14.

2x forward P/E versus 136. 0x for Corcept Therapeutics Incorporated — 121. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CORT: 40. 4% to $71. 67.

In this comparison, PAHC (1.

1% yield) pays a dividend. XERS, LNTH, SUPN, CORT do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Lantheus Holdings, Inc.

(LNTH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 47)). Both have compounded well over 10 years (LNTH: +41. 9%, XERS: -67. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: XERS is a small-cap high-growth stock; LNTH is a small-cap quality compounder stock; SUPN is a small-cap quality compounder stock; PAHC is a small-cap high-growth stock; CORT is a small-cap quality compounder stock. PAHC pays a dividend while XERS, LNTH, SUPN, CORT do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.